Scinovex
review Open AccessTop 1% cited

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets

Scientific Reports · 2018 · Vol. 8(1) · pp. 9227–9227
Ádám NagyAndrás LánczkyOtília MenyhártBalázs Győrffy

Abstract

Multiple studies suggested using different miRNAs as biomarkers for prognosis of hepatocellular carcinoma (HCC). We aimed to assemble a miRNA expression database from independent datasets to enable an independent validation of previously published prognostic biomarkers of HCC. A miRNA expression database was established by searching the TCGA (RNA-seq) and GEO (microarray) repositories to identify miRNA datasets with available expression and clinical data. A PubMed search was performed to identify prognostic miRNAs for HCC. We performed a uni- and multivariate Cox regression analysis to validate the prognostic significance of these miRNAs. The Limma R package was applied to compare the expression of miRNAs between tumor and normal tissues. We uncovered 214 publications containing 223 miRNAs identified as potential prognostic biomarkers for HCC. In the survival analysis, the expression levels of 55 and 84 miRNAs were significantly correlated with overall survival in RNA-seq and gene chip datasets, respectively. The most significant miRNAs were hsa-miR-149, hsa-miR-139, and hsa-miR-3677 in the RNA-seq and hsa-miR-146b-3p, hsa-miR-584, and hsa-miR-31 in the microarray dataset. Of the 223 miRNAs studied, the expression was significantly altered in 102 miRNAs in tumors compared to normal liver tissues. In summary, we set up an integrated miRNA expression database and validated prognostic miRNAs in HCC.

MicroRNA in disease regulationCircular RNAs in diseasesCancer-related molecular mechanisms researchmicroRNAHepatocellular carcinomaProportional hazards modelMicroarrayMicroarray analysis techniquesComputational biologySurvival analysisBiologyGene expressionBioinformatics

MeSH terms

FemaleCarcinoma, HepatocellularHumansLiver NeoplasmsMaleRNA, NeoplasmBiomarkers, TumorSurvival RateDisease-Free SurvivalDatabases, Nucleic AcidMicroRNAs

Funding

  • National Research, Development and Innovation Office
Citations
1,466
FWCI
86.97
field-weighted impact
References
49
Percentile
100%
vs. same field & year
Citations per year
References
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine · 2008 · 12,835 citations
Global cancer statistics
CA A Cancer Journal for Clinicians · 2011 · 55,006 citations
Cancer statistics, 2017
CA A Cancer Journal for Clinicians · 2017 · 14,945 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets · Scinovex